医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BISTel Showcases Smart Pharma Innovation Award Winner GrandView APM at 2021 Manufacturing Assets and Reliability Conference

2021年05月12日 AM03:54
このエントリーをはてなブックマークに追加


 

SANTA CLARA, Calif.

BISTel, a leading provider of AI asset performance management (APM) solutions for industrial manufacturing, announced today that it will feature its AI based GrandView APM solution at the annual Manufacturing Assets and Reliability in Pharma 2021 Conference.

Winner of the 2020 Pharma Manufacturing Magazine, Smart Pharma Innovation Award, GrandView APM was launched last year to help manufacturers achieve the vision of industry 4.0 by leveraging asset and factory data across the manufacturing ecosystem. The pharmaceutical industry is one of the early adopters of industry 4.0 technologies, deploying digital transformation technologies to help drive continuous improvements at factories worldwide.

“Pharma is making progress in embracing Industry 4.0 and AI based predictive maintenance is one area where they can make a quick and significant impact on the production environment,” said WK Choi, CEO, BISTel. “We are pleased to sponsor the Manufacturing Assets in Pharma conference and to demonstrate our award-winning smart pharma solution.”

BISTel’s innovative asset data centric management approach helps pharma manufactures generate deeper insights at the asset level and across the entire production environment. This approach helps connect, analyze and share knowledge across the ecosystem, using this data to create insights that drive massive continuous improvements for a sector that is constantly looking for ways to improve efficiency and reduce overall production costs.

About GrandView

At this week’s conference, the GrandView™ will show how it provides for continuous monitoring of the health and performance of factory equipment, pumps, motors, fans, and other manufacturing assets and showcase powerful data visualization for all users. Coupled with an asset health index and AI predictive analytics technology, pharma users can generate a RUL (remaining useful life) prediction, pinpointing when assets will fail. Users can also connect the GrandView APM prediction to their plant’s CMMS, EAM or ERP systems, automatically generating a work order to order parts and perform maintenance — thereby minimizing or even eliminating system downtime. In addition, GrandView is scalable and helps transition manufacturers seamlessly and cost effectively from legacy, inefficient scheduled based maintenance to AI predictive based maintenance approaches. This saves manufacturers millions of dollars in maintenance costs alone and extends the life of valuable equipment.

About BISTel

For more than 20 years, BISTel’s AI based, intelligent manufacturing solutions collect and manage data, monitor the health of equipment, optimize process flows, analyze large data, quickly identify root cause failures to mitigate risk, predicting issues before they occur and extending the life of valuable equipment and other assets through industry leading manufacturing AI predictive analytics. BISTel helps customers reduce downtime, improve yield, increase asset utilization, achieving significant production and engineering efficiencies across the factory. Founded in 2000, BISTel has more than 395 employees worldwide. The company is headquartered in South Korea, with US Headquarters in Santa Clara California, and operations throughout China, France, Singapore and Texas. BISTel’s domain expertise in manufacturing AI, includes, auto, flat panel, industrial, petrochemicals, semiconductor as well as automotive, and pharmaceutical manufacturing. For more information visit bistel.com or www.grandview-apm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006108/en/

CONTACT

Stewart Chalmers

+1 818-681-3588

stewart.chalmers@bistel.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆